Abaxis specializes in point-of-care diagnostic technologies, prominently featuring the Piccolo Xpress system, which is recognized as a gold standard in blood chemistry analysis. This innovative device provides real-time, diagnostic-grade results directly at the point of care, facilitating immediate treatment planning and enhancing patient compliance. The Piccolo Xpress utilizes a comprehensive test menu that includes over 30 general chemistry analytes, making it suitable for various medical specialties such as primary care, oncology, and pediatrics. Its design incorporates automatic quality control and calibration, ensuring reliable results that healthcare providers can trust.

In addition to the Piccolo Xpress, Abaxis offers a range of reagent discs that support a wide array of tests, including metabolic panels and lipid profiles. These discs are designed to be CLIA waived, allowing for simplified testing processes in diverse healthcare settings, from urgent care facilities to research laboratories. The technology not only aids in routine diagnostics but also plays a crucial role in monitoring the effects of experimental drugs in clinical trials, thereby contributing to advancements in medical research and patient care. Overall, Abaxis's commitment to providing efficient and accurate diagnostic solutions positions it as a valuable partner in the healthcare industry.

United States

Abaxis develops and commercializes medical device and innovative technology and services that support best medical practices, enabling practitioners to respond to the health needs of their patients, while operating point of care, onsite diagnostics for human and animal health.Abaxis is now part of Zoetis.

Abaxis

Company Details